Androgen Deprivation Therapy in Prostate Cancer and Cardiovascular Risk

EP. 1: ADT as Treatment in Metastatic Prostate Cancer

May 21st 2018

EP. 2: Burden of Cardiovascular Disease in Prostate Cancer

May 21st 2018

EP. 3: Challenges Associated with ADT in Prostate Cancer

May 21st 2018

EP. 4: Significance of GnRH Antagonists in Prostate Cancer

May 21st 2018

EP. 5: Reducing the Risk for Cardiovascular Events: PRONOUNCE

May 21st 2018

EP. 6: Cardio-Oncology in Prostate Cancer

May 21st 2018

EP. 7: Androgens and Cardiovascular Events

May 21st 2018

EP. 8: Likelihood for Cardiovascular Events After ADT

May 21st 2018

EP. 9: Metabolic Aberrations Associated With ADT

May 21st 2018

EP. 10: Predicting Risk for Metabolic Aberrations and CV Events

May 21st 2018

EP. 11: Managing Metabolic Aberrations and CV Events from ADT

May 21st 2018

EP. 12: Strategies for Preventing CV Events in Prostate Cancer

May 21st 2018

EP. 13: ADT and Cardiovascular Risk in Prostate Cancer: Q&A

May 21st 2018